October 27, 2017 — CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
October 25, 2017 — Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at ...
October 25, 2017 — Amaranth Medical will provide an update at the annual Transcatheter Cardiovascular Therapeutics (TCT) ...
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience dr ...
August 18, 2017 — Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual ...
August 3, 2017 — Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short ...
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failure ...
May 12, 2017 — PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing ...
May 1, 2017 — The U.S. Food and Drug Administration (FDA) approved Medtronic’s Resolute Onyx Drug-eluting Stent (DES) ...
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent. It was cleared by the FDA and launched ...
March 3, 2017 — Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS ...
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra PzF ...
Stents were the key focus of interventional cardiology for more than 20 years, but the focus has changed in recent years ...
DAIC has worked hard to bring useful technology news and resources to our readers. While we conduct reader surveys and ...
![Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent](/sites/default/files/styles/content_feed_large/public/field/image/X0000_Boston%20Scientific_Synergy%20stent%20closeup%203.jpg?itok=WdJy6WmK)
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers ...